Point Mutations in Two EVI1 Zn Fingers Abolish EVI1-GATA1 Interaction and Allow Erythroid Differentiation of Murine Bone Marrow Cells
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
EVI1 is an aggressive nuclear oncoprotein deregulated by recurring chromosomal abnormalities in myelodysplastic syndrome (MDS). The expression of the corresponding gene is a very poor prognostic marker for MDS patients and is associated with severe defects of the erythroid lineage. We have recently shown that the constitutive expression of EVI1 in murine bone marrow results in a fatal disease with features characteristic of MDS, including anemia, dyserythropoiesis, and dysmegakaryopoiesis. These lineages are regulated by the DNA-binding transcription factor GATA1. EVI1 has two zinc finger domains containing seven motifs at the N terminus and three motifs at the C terminus. Supported by results of assays utilizing synthetic DNA promoters, it was earlier proposed that erythroid-lineage repression by EVI1 is based on the ability of this protein to compete with GATA1 for DNA-binding sites, resulting in repression of gene activation by GATA1. Here, however, we show that EVI1 is unable to bind to classic GATA1 sites. To understand the mechanism utilized by EVI1 to repress erythropoiesis, we used a combination of biochemical assays, mutation analyses, and in vitro bone marrow differentiation. The results indicate that EVI1 interacts directly with the GATA1 protein rather than the DNA sequence. We further show that this protein-protein interaction blocks efficient recognition or binding to DNA by GATA1. Point mutations that disrupt the geometry of two zinc fingers of EVI1 abolish the protein-protein interaction, leading to normal erythroid differentiation of normal murine bone marrow in vitro.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pevny, L., Simon, M. C., Robertson, E., Klein, W. H., Tsai, S.-F., D'Agati, V., Orkin, S. H., & Costantini, F. (1991) · Nature · doi:10.1038/349257a0 · Cited by 1,308 · cited 1×
“Targeted disruption of GATA1 leads to impairment of erythropoiesis and embryonic death in mice (6, 17 ).”
BackgroundFujiwara, Y., Browne, C. P., Cunniff, K., Goff, S. C., & Orkin, S. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.22.12355 · Cited by 778
Transcriptional activation and DNA binding by the erythroid factor GF-1/NF-E1/Eryf 1.
Martin, D. I., & Orkin, S. H. (1990) · Genes & Development · doi:10.1101/gad.4.11.1886 · Cited by 409 · cited 2×
“The CF of GATA1 is essential for DNA binding, whereas the NF strengthens DNA binding and is required for interaction with FOG-1 (5, 12 , 29).”
BackgroundPU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding
Zhang, P., Zhang, X., Iwama, A., Yu, C., Smith, K. A., Mueller, B. U., Narravula, S., Torbett, B. E., Orkin, S. H., & Tenen, D. G. (2000) · Blood · doi:10.1182/blood.v96.8.2641 · Cited by 368
Tsai, S. F., Strauss, E., & Orkin, S. H. (1991) · Genes & Development · doi:10.1101/gad.5.6.919 · Cited by 327
Trainor, C. D., Omichinski, J. G., Vandergon, T. L., Gronenborn, A. M., Clore, G. M., & Felsenfeld, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.5.2238 · Cited by 223
Activation of the erythropoietin receptor promoter by transcription factor GATA-1.
Zon, L. I., Youssoufian, H., Mather, C., Lodish, H. F., & Orkin, S. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10638 · Cited by 221 · cited 2×
“These promoters contain DNA binding sites for and are activated by GATA1 (13, 33).”
BackgroundStopka, T., Amanatullah, D. F., Papetti, M., & Skoultchi, A. I. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600834 · Cited by 154 · cited 1×
“The regulation of GATA1 activity has been extensively studied, and different mechanisms have been hypothesized for its inhibition by other factors, among them PU.1 (19, 24 ).”
BackgroundPU.1 and pRB Interact and Cooperate To Repress GATA-1 and Block Erythroid Differentiation
Rekhtman, N., Choe, K. S., Matushansky, I., Murray, S., Stopka, T., & Skoultchi, A. I. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7460-7474.2003 · Cited by 102 · cited 1×
“The regulation of GATA1 activity has been extensively studied, and different mechanisms have been hypothesized for its inhibition by other factors, among them PU.1 ( 19 , 24).”
BackgroundSUV39H1 interacts with AML1 and abrogates AML1 transactivity: AML1 is methylated in vivo.
Chakraborty, S., Sinha, K. K., Senyuk, V., & Nucifora, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206600 · Cited by 71
Self-citation
Cited by
Keep Your Fingers Off My DNA: Protein–Protein Interactions Mediated by C2H2 Zinc Finger Domains
Brayer, K. J., & Segal, D. J. (2008) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-008-9008-5 · Cited by 320
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
Bejar, R., Levine, R., & Ebert, B. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1175 · Cited by 305
Lugthart, S., van Drunen, E., van Norden, Y., van Hoven, A., Erpelinck, C. A. J., Valk, P. J. M., Beverloo, H. B., Löwenberg, B., & Delwel, R. (2008) · Blood · doi:10.1182/blood-2007-10-119230 · Cited by 280
The prdm family: expanding roles in stem cells and development
Hohenauer, T., & Moore, A. W. (2012) · Development · doi:10.1242/dev.070110 · Cited by 265
“Here, we discuss some of these recent studies, which REVIEW Development 139 (13) Factor Intrinsic enzymatic activity Binding to chromatin modifiers Other co-repressors and binding partners Prdm1 G9a (Gyory et al., 2004), Lsd1 (Su et al., 2009), Hdac2 (Yu et al., 2000), Prmt5 (Ancelin et al., 2006) Groucho family (Tle1…”
PRDM proteins: important players in differentiation and disease
Fog, C. K., Galli, G. G., & Lund, A. H. (2012) · BioEssays · doi:10.1002/bies.201100107 · Cited by 201
“Dnmt3a/b [110, 111], GATA1 [49], HDAC1 [112],”
Molecular Signatures of Quiescent, Mobilized and Leukemia-Initiating Hematopoietic Stem Cells
Forsberg, E. C., Passegué, E., Prohaska, S. S., Wagers, A. J., Koeva, M., Stuart, J. M., & Weissman, I. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008785 · Cited by 127
“). Literature searches revealed that all 8 transcription factors have been implicated in hematopoiesis. In particular, Evi1 is an oncogenic transcription factor in myeloid leukemias, and may regulate normal hematopoiesis by interacting with transcription factors in the Gata family”
BackgroundShen, C., Chen, M.-T., Zhang, X.-H., Yin, X.-L., Ning, H.-M., Su, R., Lin, H.-S., Song, L., Wang, F., Ma, Y.-N., et al. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006259 · Cited by 62
“1 and GATA1 via protein—protein interaction [26,29].”
Retracted
Metadata
- Authors
- Laricchia-Robbio, L., Fazzina, R., Li, D., Rinaldi, C. R., Sinha, K. K., Chakraborty, S., & Nucifora, G.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2006-10-01
- Volume
- 26
- Issue
- 20
- Pages
- 7658-7666
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2105090556
- Cited by
- 66
- References
- 10
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.